Phosphonium Ionic Conjugates for Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents often face challenges due to undesirable physicochemical properties such as low solubility, poor bioavailability, and limited ability to cross the blood-brain barrier, leading to reduced effectiveness and increased side effects.
Innovation Solution
The development of phosphonium-based ionic conjugates (PBICs) that combine a cationic phosphonium group with anionic pharmaceutically active compounds or their derivatives, enhancing absorption, bioavailability, and therapeutic profiles by facilitating delivery to the cytosol and mitochondrial space.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phosphonium-based ionic conjugates are formed to enhance solubility and bioavailability, then absorption and therapeutic efficacy are improved, but molecular complexity and formulation complexity increase
Solution Approach 1:
The patent applies composite materials by forming ionic conjugates between phosphonium-containing compounds and pharmaceutically active compounds. This creates a composite structure where the phosphonium cation and active compound anion work together to provide both enhanced bioavailability and therapeutic activity, resolving the contradiction between improved reliability and increased complexity.
Solution Approach 2:
The patent utilizes parameter changes by modifying the physicochemical properties of the active compound through ionic conjugation with phosphonium groups. This changes the charge state, solubility characteristics, and membrane permeability parameters of the compound, thereby improving bioavailability while managing complexity through systematic property modification.
2Productivity
If ionic conjugates are designed to penetrate cell membranes and blood-brain barrier, then delivery efficiency is improved, but molecular size and structural complexity increase
Solution Approach 1:
The patent applies local quality by introducing phosphonium groups at specific locations on the active compound molecule. This localized modification provides the necessary positive charge for membrane penetration without requiring complete structural redesign, thereby improving delivery efficiency while limiting the increase in overall molecular complexity.
Solution Approach 2:
The phosphonium group acts as an intermediary that facilitates membrane penetration. It serves as a mediator between the hydrophilic active compound and the hydrophobic cell membrane, enabling efficient delivery without requiring the active compound itself to undergo extensive structural modification that would increase complexity.
3Ease of manufacture
If conventional drugs with poor solubility are used, then formulation simplicity is maintained, but absorption rates and bioavailability are reduced
Solution Approach 1:
The patent applies parameter changes by converting poorly soluble conventional drugs into ionic conjugates with improved solubility parameters. The phosphonium conjugation changes the dissolution and absorption parameters without fundamentally altering the manufacturing process, maintaining formulation simplicity while significantly improving absorption rates and bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PBICs improve the solubility, absorption, and therapeutic efficacy of pharmaceutical agents, reducing toxicity and side effects while enhancing their ability to penetrate cell membranes and the blood-brain barrier.
Implementation Method 1
an ionic conjugate comprising (a) one or more cationic compounds, wherein each cationic compound comprises a phosphonium group, and (b) an anionic compound comprising a pharmaceutically active compound
Implementation Method 2
The PBICs of the pharmaceutically active agent can have at least one enhanced physicochemical, pharmacokinetic and/or therapeutic quality, such as water solubility, hydrophilicity/hydrophobicity, permeability
Data Source
AI summary
Phosphonium-based ionic conjugates (PBICs) are described. The PBICs each include a cationic binding partner comprising a phosphonium ion and an anionic binding partner comprising a pharmaceutically active compound, or prodrug, or derivative thereof. The conjugate can have at least one enhanced physiochemical, pharmacokinetic and/or therapeutic quality as compared to the pharmaceutically active compound when not provided in a PBIC. The phosphonium-containing cationic binding partner can also serve to enhance delivery of the anionic binding partner to the cytosol and/or the inner mitochondrial space. Methods of preparing the PBICs and using the PBICs to treat disease are also described.